ArticleChemical science2015
An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent.
Article in Chemical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 133 citations in OpenAlex.
- Direct Targeting of Gene Regulators by Iridium(III) and Rhodium(III) Complexes.Accounts of chemical research · 2025Article
- SMYD5-BRD4 Interaction Drives Hepatocellular Carcinoma Progression: A Combined in Silico and Experimental Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening.Heliyon · 2024Review
- Inorganic Nanomaterials Used in Anti-Cancer Therapies:Further Developments.Nanomaterials (Basel, Switzerland) · 2023Review
- Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.Genes & diseases · 2022Article
- Homocysteine-targeting compounds as a new treatment strategy for diabetic wounds via inhibition of the histone methyltransferase SET7/9.Experimental & molecular medicine · 2022Article
- Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.Acta pharmaceutica Sinica. B · 2022Article
- Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.Journal of medicinal chemistry · 2021Review
- Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.Medicinal research reviews · 2021Review
- Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs.RSC advances · 2020Review
- The design and development of covalent protein-protein interaction inhibitors for cancer treatment.Journal of hematology & oncology · 2020Review
- Isokotomolide A from Cinnamomum kotoense Induce Melanoma Autophagy and ApoptosisOxidative medicine and cellular longevity · 2020Article
- Purified Astaxanthin fromOxidative medicine and cellular longevity · 2020Article
- Mimicking Strategy for Protein-Protein Interaction Inhibitor Discovery by Virtual Screening.Molecules (Basel, Switzerland) · 2019Review
- A luminescent microRNA nanoprobe based on the target-triggered release of an iridium(III)-solvent complex from mesoporous silica nanoparticles.Mikrochimica acta · 2019Article
- Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes.ACS omega · 2019Article
- Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.BMC cancer · 2019Article
- Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies.International journal of molecular sciences · 2019Review
- Article
- Targeting Brd4 for cancer therapy: inhibitors and degraders.MedChemComm · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromodomain-containing protein 4 (BRD4) has recently emerged as an attractive epigenetic target for anticancer therapy. In this study, an iridium(iii) complex is reported as the first metal-based, irreversible inhibitor of BRD4. Complex
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.